No more invasive or painful methods!
Detection of prostate cancer.
ProstaGEN
New diagnostic technology
In recent years, new diagnostic methods have been developed, based on the detection and quantification of the PCA3 gene. PCA3 is a specific gene for prostate cancer since it is only produced by cells that have undergone transformation to prostate cancer.
The main advantage of measuring this molecular marker is that the result of this analysis is not affected by non-cancerous prostatic diseases such as Benign Prostatic Hyperplasia (BPH) or Prostatitis.
With a simple urine sample, prostate cancer can be identified early.
This test offers up to 92% certainty in the diagnosis for prostate cancer.
The detection of prostate cancer with blood analysis of PSA and digital rectal examination (TR) is 24-37% (1).
This is due to the fact that PSA is a protein normally produced by prostate cells which, when seen, increases its value in blood serum, it is only an indicator of prostatic tissue inflammation, which does not mean cancer.
